Lung surfactant protein-A and carcinoembryonic antigen in pleural effusions due to lung adenocarcinoma and malignant mesothelioma

Lung surfactant protein-A (SP-A) is a major phospholipid-associated glycoprotein in surfactant, and is a useful immunohistochemical marker for lung adenocarcinoma. Carcinoembryonic antigen (CEA) has not been immunohistochemically detected in mesothelioma. In pleural effusions due to malignant mesothelioma, very low concentrations of SP-A and CEA can be expected. We studied the value of combined determinations of CEA and SP-A in pleural fluid to distinguish between lung adenocarcinoma and mesothelioma. SP-A and CEA concentrations were measured in pleural effusions from 78 patients with lung adenocarcinoma and 10 with malignant mesothelioma. SP-A concentrations in pleural effusions due to lung adenocarcinoma and mesothelioma were 516 +/- 140 and 16.9 +/- 3.6 ng.ml-1 (mean +/- SEM), respectively. CEA concentrations in pleural effusions due to lung adenocarcinoma and mesothelioma were 239 +/- 92.4 and 1.7 +/- 0.3 ng.ml-1, respectively. SP-A values did not exceed 100 ng.ml-1 in any of 10 mesotheliomas, whilst in 37 of 78 lung adenocarcinomas they did. CEA values did not exceed 10 ng.ml-1 in any of 10 mesotheliomas, whilst in 53 of 78 lung adenocarcinomas they did. Increased values of SP-A and/or CEA were found in pleural effusions from 67 of 78 lung adenocarcinomas. It is concluded that a combination of CEA and SP-A assays in pleural effusions will be helpful for discriminating lung adenocarcinoma from mesothelioma.

This article has been cited by other articles:

				F. Jiang, N. P. Caraway, B. Nebiyou Bekele, H.-Z. Zhang, A. Khanna, H. Wang, R. Li, R. L. Fernandez, T. M. Zaidi, D. A. Johnston, et al. Surfactant Protein A Gene Deletion and Prognostics for Patients with Stage I Non-Small Cell Lung Cancer Clin. Cancer Res., August 1, 2005; 11(15): 5417 - 5424. [Abstract] [Full Text] [PDF]

				A S Abutaily, B J Addis, and W R Roche Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies J. Clin. Pathol., September 1, 2002; 55(9): 662 - 668. [Abstract] [Full Text] [PDF]

				V.B. Antony, R. Loddenkemper, P. Astoul, C. Boutin, P. Goldstraw, J. Hott, F. Rodriguez Panadero, and S.A. Sahn Management of malignant pleural effusions Eur. Respir. J., August 1, 2001; 18(2): 402 - 419. [Full Text] [PDF]

				M. Paganuzzi, M. Onetto, P. Marroni, R. Filiberti, E. Tassara, S. Parodi, and R. Felletti Diagnostic Value of CYFRA 21-1 Tumor Marker and CEA in Pleural Effusion Due to Mesothelioma Chest, April 1, 2001; 119(4): 1138 - 1142. [Abstract] [Full Text] [PDF]

				Management of Malignant Pleural Effusions Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1987 - 2001. [Full Text]

				R. J. Mason, M. Kalina, L. D. Nielsen, A. M. Malkinson, and J. M. Shannon Surfactant Protein C Expression in Urethane-Induced Murine Pulmonary Tumors Am. J. Pathol., January 1, 2000; 156(1): 175 - 182. [Abstract] [Full Text] [PDF]

				C. HERMANS, O. LESUR, B. WEYNAND, TH. PIETERS, M. LAMBERT, and A. BERNARD Clara Cell Protein (CC16) in Pleural Fluids . A Marker of Leakage through the Visceral Pleura Am. J. Respir. Crit. Care Med., March 1, 1998; 157(3): 962 - 969. [Abstract] [Full Text] [PDF]